Pemigatinib
Sign in to save this workspacePrimary targets: FGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.23
Gini
0.718
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pemigatinib. Strongest target: FGFR1 at 99.9% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR1 | 99.9% | 0.1% |
| 2 | FGFR3 | 99.4% | 0.6% |
| 3 | FGFR2 | 98.7% | 1.3% |
| 4 | EIF2AK1 | 97.7% | 2.3% |
| 5 | FMS | 95.5% | 4.5% |
| 6 | FGFR4 | 93.9% | 6.1% |
| 7 | FLT4_VEGFR3 | 92.1% | 7.9% |
| 8 | EIF2AK2 | 85.3% | 14.7% |
| 9 | FLT1_VEGFR1 | 84.7% | 15.3% |
| 10 | MLK2_MAP3K10 | 81.3% | 18.7% |
| 11 | TAOK2_TAO1 | 80.3% | 19.7% |
| 12 | SIK3 | 79.4% | 20.6% |
| 13 | MST3_STK24 | 74.4% | 25.6% |
| 14 | STK25_YSK1 | 72.5% | 27.5% |
| 15 | GLK_MAP4K3 | 70.8% | 29.2% |
| 16 | MEKK2 | 67.2% | 32.8% |
| 17 | C_KIT | 65.4% | 34.6% |
| 18 | CDK6_CYCLIN_D3 | 63.3% | 36.7% |
| 19 | LYN | 61.7% | 38.3% |
| 20 | NEK1 | 59.0% | 41.0% |
Selectivity landscape
Where Pemigatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pemigatinib.
Atlas insights for Pemigatinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1200.51 | |
| ALLOGRAFT_REJECTION | 4014.42 | |
| ANDROGEN_RESPONSE | 1111.07 | |
| ANGIOGENESIS | 655.23 | |
| APICAL_JUNCTION | 4331.61 | |
| APICAL_SURFACE | 380.90 | |
| APOPTOSIS | 2972.47 | |
| BILE_ACID_METABOLISM | 521.28 | |
| CHOLESTEROL_HOMEOSTASIS | 662.12 | |
| COAGULATION | 417.68 | |
| COMPLEMENT | 2533.10 | |
| DNA_REPAIR | 996.31 | |
| E2F_TARGETS | 2472.48 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 807.65 | |
| ESTROGEN_RESPONSE_EARLY | 1475.64 | |
| ESTROGEN_RESPONSE_LATE | 1536.52 | |
| FATTY_ACID_METABOLISM | 575.53 | |
| G2M_CHECKPOINT | 1944.34 | |
| GLYCOLYSIS | 1618.59 | |
| HEDGEHOG_SIGNALING | 287.91 | |
| HEME_METABOLISM | 992.37 | |
| HYPOXIA | 2171.16 | |
| IL2_STAT5_SIGNALING | 1384.49 | |
| IL6_JAK_STAT3_SIGNALING | 2902.27 | |
| INFLAMMATORY_RESPONSE | 2066.98 | |
| INTERFERON_ALPHA_RESPONSE | 305.66 | |
| INTERFERON_GAMMA_RESPONSE | 3237.39 | |
| KRAS_SIGNALING_DN | 428.54 | |
| KRAS_SIGNALING_UP | 1678.47 | |
| MITOTIC_SPINDLE | 2793.59 | |
| MTORC1_SIGNALING | 1944.10 | |
| MYC_TARGETS_V1 | 1582.28 | |
| MYC_TARGETS_V2 | 305.31 | |
| MYOGENESIS | 1418.35 | |
| NOTCH_SIGNALING | 141.90 | |
| OXIDATIVE_PHOSPHORYLATION | 937.26 | |
| P53_PATHWAY | 1623.21 | |
| PANCREAS_BETA_CELLS | 252.64 | |
| PEROXISOME | 420.97 | |
| PI3K_AKT_MTOR_SIGNALING | 5094.29 | |
| PROTEIN_SECRETION | 1097.21 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 177.75 | |
| SPERMATOGENESIS | 620.09 | |
| TGF_BETA_SIGNALING | 885.96 | |
| TNFA_SIGNALING_VIA_NFKB | 1873.26 | |
| UNFOLDED_PROTEIN_RESPONSE | 734.30 | |
| UV_RESPONSE_DN | 2150.27 | |
| UV_RESPONSE_UP | 1761.36 | |
| WNT_BETA_CATENIN_SIGNALING | 972.18 | |
| XENOBIOTIC_METABOLISM | 1052.17 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.840 |
| SRR23303752 | — | 0.831 |
| SRR10899984 | — | 0.816 |
| aMVAC.P_005_TURBT_S223 | — | 0.816 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.814 |
Annotations
Sign in to read and post annotations.
Loading…